Seer, Inc. announced its participation at the 2026 ASMS Annual Conference to showcase its AI-driven multi-cancer screening approach and advanced proteomics technology. The company will present early results from a large collaboration analyzing over 20,000 plasma samples with Korea University, highlighting scalable, sensitive cancer screening. Seer will also introduce Radiant DIA™, a new data processing tool designed to speed up proteomics analysis, enabling faster biomarker discovery and precision medicine. These developments mark a significant step in applying proteomics to population-scale health research and precision diagnostics.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Bragar Eagel & Squire, P.C. is investigating Starfighters Space, Inc. following the resignation of its founder and CEO Rick Svetkoff and company secretary Brenda Svetkoff due to disagreements with the board over company operations. The company disput...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
